<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159705">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01838694</url>
  </required_header>
  <id_info>
    <org_study_id>IVXCpn001</org_study_id>
    <nct_id>NCT01838694</nct_id>
  </id_info>
  <brief_title>Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With SLE.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Invion, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Invion, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety, tolerability, and efficacy of
      4 weeks intravenous treatment with Cpn10 in subjects with mildly active SLE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction from baseline serum Interleukin 6 (IL-6) levels at the end of active dosing, comparing treatment to placebo cohort.</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ala-Cpn10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range (0.16mg/kg [10mg twice weekly] to 5mg/kg [300mg twice weekly]) administered intravenously by infusion over 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ala-Cpn10</intervention_name>
    <arm_group_label>Ala-Cpn10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (ALL must be met):

        To be entered on study, subjects must meet the following criteria:

          1. Male or female

          2. Age 18 -  75 years

          3. Patients fulfilling at least 4 criteria for Systemic Lupus Erythematosus (SLE) as
             defined by the American College of Rheumatology (ACR)

          4. Present with mild active SLE disease

          5. Laboratory values as follows:

             i) ANA titer ≥ 1:160 or positive anti-dsDNA antibodies at any time prior to screening

          6. Not pregnant or breast-feeding

          7. Able to tolerate a stable dose of corticosteroids of ≤ 0.3 mg/kg/day of
             prednisone or equivalent for the duration of the study

          8. Agreement to use an effective form of contraception for the duration of the study.

          9. Ability to understand and give consent.

         10. Willing to participate and able to comply with the study requirements, procedures and
             visits.

        Exclusion Criteria (NONE can apply):

          1. Active severe SLE flare with central nervous system (CNS) manifestations, active
             renal lupus, active pericarditis, active pleuritis, active peritonitis or other SLE
             manifestations requiring treatment not allowed by the study protocol within 4 weeks
             of screening

          2. Active lupus nephritis and/or severe renal impairment (estimated or measured
             glomerular filtration rate (GFR) &lt; 50%)

          3. Pregnancy.

          4. Lack of peripheral venous access.

          5. Significant history of arterial or venous thrombosis (blood clots) within 12 months
             prior to trial start.

          6. Requirement for a stable dose of corticosteroid ≥ greater than 0.3 mg/kg/day of
             prednisone or equivalent.

          7. Any therapy with human or murine antibodies.

          8. Any experimental therapy within 3 months.

          9. Therapy with cyclophosphamide; pulse methylprednisolone or i.v. Ig within 4-6 weeks.

         10. Subjects with any the following laboratory abnormalities: serum creatinine &gt;3.0
             mg/dL, white blood cells (WBC) &lt;3,500/μL, absolute neutrophil count (ANC) &lt;3,000/μL,
             absolute lymphocyte count ≤500/μL, Hgb &lt;8.0 g/dL, platelets &lt;50,000/μL, alanine
             aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt;1.5 x upper limit of
             normal (ULN), alkaline phosphatase &gt;1.5 ULN,

         11. Personal or psychiatric condition that precludes the subject being able to comply
             with the study requirements or unable to undergo informed consent process.

         12. History of severe systemic bacterial, fungal, viral, or parasitic infections. Have
             required management or hospitalization of any infection within the last 4 weeks
             before screening.

         13. History of malignancy - except completely excised basal cell carcinoma.

         14. Impaired hepatic function

         15. Body weight of 260lbs/120kg or more (BMI &gt; 35)

         16. Tuberculosis (TB) or active treatment for TB

         17. History of alcohol or substance abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Altoona Arthritis and Osteoporosis Center</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Madonna</last_name>
      <phone>814-693-0300</phone>
      <email>traceymadonna1125@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Alan Kivitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 21, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
